Literature DB >> 12695241

The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.

Nicola Orzalesi1, Luca Rossetti, Andrea Bottoli, Elena Fumagalli, Paolo Fogagnolo.   

Abstract

OBJECTIVE: To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
METHODS: In this crossover study, 10 patients with POAG and 10 with OHT were treated with latanoprost once a day, brimonidine twice a day, and a fixed combination of timolol and dorzolamide twice a day for 1 month. Four 24-hour tonometric curves were obtained for each patient. Intraocular pressure (IOP) was measured at 3, 6, and 9 AM, and at noon and at 3, 6, and 9 PM, and at midnight, using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slitlamp. MAIN OUTCOME MEASURE: Reduction of circadian IOP.
RESULTS: All the drugs significantly reduced IOP compared with the baseline at all times, except for brimonidine at midnight, 3 AM, and 6 AM. Latanoprost was more effective than brimonidine in lowering IOP at 3 and 6 AM and at 3 PM (P=.03), and the combination of timolol and dorzolamide was more effective than brimonidine at 3 and 9 AM (P=.04) and at 3 and 6 PM (P =.05) and more effective than latanoprost at 9 AM (P=.05).
CONCLUSION: Latanoprost and the fixed combination of timolol and dorzolamide led to similar circadian reductions in IOP, whereas brimonidine was less effective, particularly during the night.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695241     DOI: 10.1001/archopht.121.4.453

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  20 in total

1.  Circadian variations in central corneal thickness and intraocular pressure in patients with glaucoma.

Authors:  P Fogagnolo; L Rossetti; F Mazzolani; N Orzalesi
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

Review 2.  Glaucoma medications: use and safety in the elderly population.

Authors:  Elliott Kanner; James C Tsai
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs.

Authors:  Kenji Inoue; Minako Shiokawa; Michitaka Sugahara; Masato Wakakura; Shoichi Soeda; Goji Tomita
Journal:  Jpn J Ophthalmol       Date:  2012-09-22       Impact factor: 2.447

4.  Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Authors:  Chandrasekar Durairaj
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 5.  Management of glaucoma: focus on pharmacological therapy.

Authors:  Robert E Marquis; Jess T Whitson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Effect of 1% brinzolamide and 0.5% timolol fixed combination on intraocular pressure after cataract surgery with phacoemulsification.

Authors:  Kemal Ornek; Nesrin Büyüktortop; Nurgül Ornek; Reyhan Oğurel; Inci Elif Erbahçeci; Zafer Onaran
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

7.  Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.

Authors:  Jason Yeh; Daniel Kravitz; Brian Francis
Journal:  Clin Ophthalmol       Date:  2008-06

8.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

9.  A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients.

Authors:  R Jothi; A M Ismail; R Senthamarai; Siddhartha Pal
Journal:  Indian J Pharmacol       Date:  2010-12       Impact factor: 1.200

10.  Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.

Authors:  Chandrasekar Durairaj; Jie Shen; Madhu Cherukury
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.